Journal ArticleJ Oncol Pharm Pract · April 2019
BACKGROUND: Immune checkpoint inhibitors are poised to revolutionize the management of a growing number of malignancies. Unfortunately, the management of steroid-refractory immune mediated adverse events is based on a paucity of randomized data and limited ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2017
e19512 Background:Multiple Myeloma (MM) is a relatively common malignancy in Eastern NC, especially in African American population. There have been several advances in treatment of MM but it is unclear how well current therapies ...
Full textCite
Conference
Background: Immune checkpoint inhibitors have shown promising responses in advanced lung cancer as well as a number of other malignancies. However, efficacy appears to be variable based on the site of disease. We reviewed the outcomes of patients with lu ...
Cite
